Inhalation Sciences

The unmet need for a targeted, efficacious inhaled antibiotic treatment for the growing number of patients hospitalized with lower respiratory tract infections (LRTIs) has become increasingly clear following the Covid-19 pandemic. The APRINHA project aims to address that unmet need. It will develop new inhaled formulations of an antibiotic that can both treat LRTIs and help reduce antibiotic resistance. The new formulations aim to improve drug deposition, retention, and penetration.

The project will last 36 months. Seven organizations are part of the consortium taking part, including RISE, the Research Institute of Sweden. All bring outstanding expertise in inhalation and pulmonary drug delivery with strong track records in contributing to multidisciplinary cross-border research projects. In this project, ISAB will collaborate with the inhalation team at RISE and be using its in vivo PreciseInhale equipment in RISE research facilities to carry out pharmacokinetic (PK) studies of the new formulations.

Manoush Masarrat, CEO ISAB: "We are pleased to be playing a part and would like to thank the team at the Institute of Medical Microbiology at UZH for initiating and coordinating the project. The unmet need for better formulations of antibacterial inhalation products that are active against drug-resistant respiratory infections is urgent. This project addresses that need."

Read ISAB's June 9 2022 Press Release on its joint funding proposal to APRINHA with RISE here.